List of Excipients in Branded Drug TAGAMET

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Prestige Brands Holdings Inc	TAGAMET	cimetidine	52183-223	CELLULOSE, MICROCRYSTALLINE
Prestige Brands Holdings Inc	TAGAMET	cimetidine	52183-223	FD&C BLUE NO. 1 ALUMINUM LAKE
Prestige Brands Holdings Inc	TAGAMET	cimetidine	52183-223	HYPROMELLOSES
Prestige Brands Holdings Inc	TAGAMET	cimetidine	52183-223	MAGNESIUM STEARATE
Prestige Brands Holdings Inc	TAGAMET	cimetidine	52183-223	POLYETHYLENE GLYCOL

TAGAMET Excipient Strategy and Commercial Opportunities for Cimetidine

Last updated: August 18, 2026

Tagamet contains cimetidine, a small-molecule histamine H2-receptor antagonist. Its core composition-of-matter and conventional tablet patents have expired, and the U.S. market is genericized. Commercial opportunity now depends on differentiated delivery, excipient tolerability, OTC positioning, geographic expansion, and low-cost manufacturing rather than exclusivity for cimetidine itself.

What is Tagamet and which excipients are used?

Tagamet and Tagamet HB contain cimetidine, generally in 200 mg, 300 mg, 400 mg, and 800 mg strengths for prescription products, with 200 mg as the principal OTC strength. Cimetidine suppresses gastric acid secretion by blocking histamine H2 receptors on gastric parietal cells. [1,2]

A representative cimetidine immediate-release tablet uses the following excipient architecture:

Excipient	Primary function	Commercial or technical consideration
Lactose monohydrate	Diluent and tablet-volume builder	Cost-effective but unsuitable for certain lactose-intolerant or lactose-avoidant consumers
Microcrystalline cellulose	Filler and dry-binder	Supports compactibility and tablet robustness
Crospovidone	Superdisintegrant	Promotes rapid tablet breakup
Sodium starch glycolate	Superdisintegrant	Supports dissolution but can increase swelling and sensitivity to compression conditions
Povidone	Binder	Improves granulation and mechanical strength
Magnesium stearate	Lubricant	Excess levels can slow wetting and dissolution
Hypromellose	Film former and coating polymer	Enables moisture, color and handling control
Polyethylene glycol	Plasticizer	Improves coating flexibility
Titanium dioxide	Opacifier and colorant	Subject to jurisdiction-specific regulatory scrutiny
Carnauba wax	Polishing or coating aid	Supports appearance and handling characteristics

The exact excipient list varies by manufacturer, strength, country and dosage form. The current U.S. Tagamet HB label identifies inactive ingredients including carnauba wax, crospovidone, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone, sodium starch glycolate and titanium dioxide. [1]

The formulation is technically conventional. The main development variables are disintegration, dissolution, tablet size, coating performance, powder flow, dose uniformity and consumer acceptability.

What excipient strategy is most appropriate for Tagamet?

The strongest strategy is a segmented platform rather than a single reformulation. Cimetidine is a high-dose active relative to many OTC products, so excipients must support manufacturability without producing an unnecessarily large tablet.

Standard immediate-release tablet

The conventional tablet remains the lowest-cost option. A lactose-based formulation using microcrystalline cellulose, crospovidone, sodium starch glycolate and magnesium stearate is suitable for high-volume production.

A direct-compression design could reduce processing steps, but cimetidine powder properties, drug loading and tablet weight must support reliable content uniformity. A wet-granulated design may provide better flow and compression performance where the active has poor tableting characteristics.

The commercial objective is cost reduction, not clinical differentiation. Opportunities include:

• Lower tablet weight.
• Reduced coating-material use.
• Better line speed and yield.
• Lower magnesium stearate loading without dissolution loss.
• Simplified excipient sourcing.
• A common platform across 200 mg, 300 mg, 400 mg and 800 mg strengths.

Lactose-free formulation

A lactose-free tablet is a practical line extension. Lactose can be replaced with combinations of microcrystalline cellulose, mannitol, dibasic calcium phosphate, starch or other suitable diluents.

Mannitol is attractive for chewable or orally disintegrating products because it provides a cooling sensation and relatively favorable mouthfeel. Dibasic calcium phosphate can reduce hygroscopicity and improve compactibility, although it may require careful control of dissolution and tablet hardness.

A lactose-free claim can support pharmacy and e-commerce differentiation, but it does not create meaningful patent protection by itself. Any commercial value would depend on consumer targeting, packaging, search visibility and distribution.

Dye-free and low-additive formulation

A dye-free tablet could appeal to consumers seeking simpler OTC formulations. Removing colorants also simplifies global registration because color additive permissions vary by jurisdiction.

A minimal-excipient product could use:

• Cimetidine.
• Microcrystalline cellulose or mannitol.
• Crospovidone.
• Povidone or another binder.
• Magnesium stearate or an alternative lubricant.
• A clear or uncoated presentation.

This strategy may reduce formulation complexity, but tablet appearance and brand recognition can suffer. Packaging would need to communicate the product difference clearly.

Chewable tablet

A 200 mg chewable tablet is one of the most commercially credible differentiated forms. It could improve convenience for occasional heartburn users who do not want to swallow a conventional tablet.

The formulation would require:

• Mannitol or another palatable diluent.
• Taste masking for cimetidine’s bitter profile.
• A flavor system compatible with the active and packaging.
• A low-grit compression profile.
• Controlled friability and adequate mechanical strength.
• Moisture protection.

The principal risk is taste. Cimetidine is not naturally suited to an unmasked chewable dosage form. Polymer coating, ion-exchange resin complexation, sweetener systems and flavor encapsulation are possible approaches, but each adds cost and may affect dissolution.

Orally disintegrating tablet

An orally disintegrating tablet could provide a portability and swallowing advantage. The active dose makes this more difficult than a low-dose antihistamine or analgesic product.

The preferred excipient system would likely include mannitol, crospovidone, a highly compactible filler, a low-level binder and a taste-masking system. Packaging would need to control moisture. ODT commercialization would require reliable disintegration, acceptable mouthfeel and evidence that the formulation does not materially alter exposure.

An ODT has greater differentiation potential than a standard tablet, but the addressable market is constrained by cimetidine’s declining clinical relevance and the availability of other H2 blockers.

Oral liquid or unit-dose sachet

A liquid could serve pediatric, geriatric or dysphagia markets, although cimetidine’s drug-interaction profile limits its attractiveness for broad self-care use.

The liquid formulation would require evaluation of:

• pH stability.
• Preservative compatibility.
• Solubility and precipitation risk.
• Container-closure compatibility.
• Flavor and bitterness.
• Microbial control.
• In-use stability.

A unit-dose sachet or stick pack could support travel and convenience, but the packaging cost would be high relative to generic cimetidine pricing.

What formulation patents protect Tagamet?

No active U.S. patent protection is identified for cimetidine as a molecule or for the conventional Tagamet immediate-release tablet. The original cimetidine patent estate expired decades ago, and standard cimetidine tablets are available from multiple generic manufacturers.

IP category	Status	Commercial consequence
Cimetidine composition of matter	Expired	No molecule-level exclusivity
Conventional immediate-release tablet	Expired or nonexclusive	Generic competition
Standard tablet excipient combinations	Generally unprotected or readily designed around	Weak barrier
Chewable formulation	Potentially patentable only if technically differentiated	Possible limited formulation exclusivity
ODT and taste masking	Potential patent opportunity	Depends on novel composition and performance
Modified-release delivery	Potentially patentable	Clinical and regulatory value must justify complexity
Manufacturing process	Potentially protectable	Usually a trade-secret or process-optimization asset
Packaging and dosing system	Potentially protectable	Limited value without strong consumer adoption
Method of use	Historic claims largely expired	Narrow new-use opportunities require supporting evidence

A new patent would need more than a routine substitution of lactose with mannitol or the use of a conventional disintegrant. Stronger claims could cover a specific taste-masking composition, release profile, stability improvement, excipient ratio, dosage form or manufacturing process supported by comparative data.

When did Tagamet lose exclusivity?

Tagamet lost meaningful U.S. market exclusivity after expiration of the original cimetidine patent estate and subsequent generic entry. Cimetidine has been generic for many years, and no current U.S. regulatory exclusivity period materially protects conventional Tagamet products.

The commercial timeline is:

Period	Event	Impact
1970s	Cimetidine developed and introduced	Originator market formation
1977	FDA approval of Tagamet reported in historical FDA materials	Prescription acid-suppression market entry [3]
1980s-1990s	Patent and market expansion	High-value branded product period
1990s	Generic cimetidine availability expanded	Price and share erosion
2000s onward	H2-blocker and PPI competition increased	Declining strategic importance
Current market	Generic cimetidine and OTC Tagamet HB coexist	Differentiation depends on brand and formulation

What is the Orange Book status of Tagamet?

The Orange Book lists approved drug products and relevant patent and exclusivity information for FDA-approved products. Cimetidine’s conventional products do not have an active composition-of-matter exclusivity position comparable with recently launched branded drugs. [4]

Tagamet’s commercial position is different from that of a newly approved NDA product:

• Conventional cimetidine tablets face generic substitution.
• No current Paragraph IV campaign is a central market event for the mature product.
• A new cimetidine dosage form could require an NDA supplement, a new NDA, or another FDA pathway depending on the proposed change.
• OTC products must comply with the applicable FDA monograph or obtain approval through an NDA pathway, depending on the product and formulation. [5]

A reformulated product may obtain regulatory approval without obtaining meaningful patent protection. Regulatory approval and market exclusivity are separate assets.

Which companies compete with Tagamet?

Tagamet competes in two distinct markets: cimetidine generics and broader acid-reduction products.

Cimetidine competitors

Generic cimetidine products are marketed by multiple companies, including manufacturers and labelers serving the prescription and OTC channels. Competition is primarily based on:

• Wholesale acquisition cost.
• Pharmacy availability.
• Contract manufacturing.
• Supply reliability.
• National drug code coverage.
• Formulation simplicity.
• Wholesaler and pharmacy purchasing agreements.

Therapeutic competitors

The broader H2-antagonist and acid-suppression market includes:

Product	Active ingredient	Competitive position
Pepcid	Famotidine	Stronger current H2-blocker brand position
Zantac legacy products	Ranitidine	Historic competitor; U.S. ranitidine products were withdrawn after NDMA-related regulatory action
Prilosec OTC	Omeprazole	Proton-pump inhibitor with strong OTC presence
Prevacid 24HR	Lansoprazole	Proton-pump inhibitor competitor
Nexium 24HR	Esomeprazole	Premium OTC proton-pump inhibitor
Antacids	Calcium carbonate, magnesium hydroxide and related actives	Rapid symptom relief and low price

Cimetidine has a clinically important disadvantage: it inhibits several cytochrome P450 enzymes and can interact with multiple medicines. Famotidine is often preferred when an H2 blocker is appropriate because of its lower interaction burden. [6]

What commercial opportunities exist for Tagamet excipient innovation?

The most credible opportunities are limited but identifiable.

1. Lactose-free OTC product

This is the lowest-risk line extension. It can use established excipients and standard immediate-release performance. The opportunity is strongest in pharmacy, e-commerce and private-label channels where ingredient filters influence purchase decisions.

2. Chewable heartburn product

A flavored chewable product could compete on convenience rather than pharmacology. The main development barrier is cimetidine taste masking. A successful product would need rapid dissolution after chewing, good mouthfeel and stable flavor performance.

3. ODT for swallowing difficulty

An ODT could target older adults and consumers with difficulty swallowing. The dose makes tablet size and taste critical. A blister-based moisture barrier would likely be required.

4. Pediatric or geriatric liquid

A liquid could address patients unable to use tablets. Its value is higher in prescription channels and institutional care than in mass-market OTC retail. Labeling, dosing accuracy and interaction concerns would constrain broad consumer adoption.

5. International licensing

Cimetidine remains commercially relevant in some markets where low-cost H2 antagonists are used and PPI access is constrained. Licensing opportunities could include:

• Regional Tagamet branding.
• Local manufacture under quality agreements.
• OTC registration support.
• Hospital and government tenders.
• Combination or convenience packaging.
• Pediatric and geriatric dosage forms.

The best licensing structure would likely involve a formulation or manufacturing asset, not rights to standard cimetidine tablets.

How strong is the patent estate for a new Tagamet formulation?

A conventional reformulation would have weak patent strength. Patentability improves when the product solves a measurable technical problem.

Proposed innovation	Patent strength	Regulatory and commercial value
Replace lactose with mannitol	Low	Moderate consumer differentiation
Remove colorants	Low	Moderate labeling and global-registration benefit
Reduce tablet weight	Low to moderate	Manufacturing benefit
Novel cimetidine taste-masking matrix	Moderate to strong	High if sensory and dissolution data are superior
ODT with defined disintegration and stability profile	Moderate	Moderate to high
Sustained-release cimetidine	Moderate	Unclear clinical value
Novel combination with another active	Variable	Requires clinical and interaction evaluation
Proprietary manufacturing process	Moderate as trade secret	Cost and supply-chain benefit

The strongest protection would combine composition claims, dosage-form claims, process claims and data-supported performance claims. A patent strategy based only on excipient identity is vulnerable to design-around.

What manufacturing and IP barriers affect cimetidine products?

Manufacturing barriers are manageable. Cimetidine is a mature small molecule with established tablet-processing experience. The main operational issues are:

• Active pharmaceutical ingredient supply qualification.
• Control of powder flow and segregation.
• Compression at high drug loading.
• Lubricant impact on dissolution.
• Moisture protection for ODTs and chewables.
• Taste masking without delaying release.
• Consistent assay across multiple tablet strengths.
• Stability of flavors, sweeteners and coating systems.
• Supply continuity for specialty excipients.

The highest barrier is commercial scale, not technical feasibility. A new formulation must justify additional tooling, stability studies, packaging and regulatory work in a category with low generic pricing and strong substitution.

What generic launch risks exist for a new Tagamet product?

A standard tablet faces immediate generic substitution and limited pricing power. A differentiated product can reduce direct substitutability, but FDA approval does not prevent competitors from launching alternative cimetidine formulations unless enforceable patents or regulatory exclusivity apply.

Key risks include:

1. A generic manufacturer launching a similar lactose-free or dye-free tablet.
2. Pharmacy substitution away from a branded product.
3. Low consumer willingness to pay for cimetidine over famotidine.
4. Clinical reluctance caused by cimetidine drug interactions.
5. Limited reimbursement for premium dosage forms.
6. Retail shelf competition from proton-pump inhibitors and antacids.
7. Formulation patents being narrowed or designed around.
8. Low production volumes causing unfavorable unit economics.

What litigation and Paragraph IV activity affect Tagamet?

No major current U.S. litigation or Paragraph IV campaign is identified as a material commercial threat to conventional Tagamet or generic cimetidine. The product is mature, and its principal legal risk is ordinary generic competition rather than an active patent dispute.

A future reformulated cimetidine product could generate Paragraph IV risk if it relies on newly issued formulation patents. The practical defense would require:

• Narrow but technically meaningful claims.
• Comparative dissolution and stability data.
• Demonstrated sensory or usability advantages.
• Clear patent listing strategy where permitted.
• Early monitoring of ANDA filings and FDA patent certifications.

Key Takeaways

• Tagamet contains cimetidine, a mature small-molecule H2 antagonist with no meaningful current molecule-level exclusivity.
• The standard excipient system is conventional and inexpensive.
• Lactose-free, dye-free, chewable and orally disintegrating forms offer the clearest formulation opportunities.
• Taste masking is the principal technical challenge for chewable and ODT products.
• A routine excipient substitution would have weak patent strength.
• New value is more likely to come from consumer positioning, manufacturing efficiency, regional licensing and dosage-form convenience.
• Cimetidine’s CYP-mediated drug-interaction profile limits its ability to compete directly with famotidine.
• Conventional Tagamet products face generic substitution, while a differentiated formulation would need strong technical data and disciplined cost control.
• No current major Paragraph IV or patent-litigation event materially changes the commercial outlook for standard cimetidine products.
• A new product should be evaluated as an OTC or specialty-formulation play, not as a conventional branded-drug exclusivity opportunity.

FAQs

Can cimetidine be formulated without lactose?

Yes. Lactose can be replaced with microcrystalline cellulose, mannitol, dibasic calcium phosphate, starch or other suitable diluents. The replacement must preserve tablet strength, disintegration, dissolution and stability.

Is Tagamet suitable for an orally disintegrating tablet?

Cimetidine can be developed as an ODT, but the 200 mg dose and bitter taste create formulation constraints. Taste masking, tablet size, moisture protection and mouthfeel are the principal development issues.

Could a new cimetidine formulation receive patent protection?

Yes, if the formulation includes a novel and non-obvious composition, release profile, stability improvement, taste-masking system or manufacturing process. Routine use of common excipients would generally provide weak protection.

Does cimetidine have biosimilar risk?

No. Cimetidine is a small molecule, so it is subject to generic-drug competition rather than biosimilar competition.

Is famotidine a stronger commercial platform than cimetidine?

Famotidine generally has the stronger current commercial platform because it has a lower drug-interaction burden and broader contemporary H2-blocker use. Cimetidine opportunities are more dependent on low cost, legacy brand recognition and differentiated dosage forms.

References

1. DailyMed. (n.d.). Tagamet HB-200: Cimetidine tablet, film coated. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (n.d.). Cimetidine prescribing information. FDA.
3. U.S. Food and Drug Administration. (1977). Tagamet approval history and product information. FDA.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
5. U.S. Food and Drug Administration. (2024). Over-the-counter monograph drugs. FDA.
6. U.S. National Library of Medicine. (2024). Cimetidine: Drug interactions and clinical pharmacology. MedlinePlus and DailyMed.